{
    "Clinical Trial ID": "NCT00313170",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Fulvestrant 250 mg",
        "Fulvestrant 250 mg",
        "INTERVENTION 2: ",
        "  Fulvestrant 250 mg + Loading Dose",
        "  Fulvestrant 250 mg + Loading Dose"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.",
        "  Requiring hormonal treatment.",
        "  Postmenopausal women (woman who has stopped having menstrual periods)",
        "Exclusion Criteria:",
        "  Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.",
        "  Treatment with more than one previous regimen of endocrine therapy for advanced BC.",
        "  An existing condition that prevents compliance."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Objective Response (ORR)",
        "  Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions). All patients were to be followed up every 12 weeks for progression, defined by response evaluation criteria in solid tumors (RECIST v1.1).",
        "  Time frame: The planned data cut-off for this study was when all patients, except withdrawals, had been followed up for at least 24 weeks. Patients received treatment up to approximately 2 years.",
        "Results 1: ",
        "  Arm/Group Title: Fulvestrant 250 mg",
        "  Arm/Group Description: Fulvestrant 250 mg",
        "  Overall Number of Participants Analyzed: 47",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of patients  8.5        (2.4 to 20.4)",
        "Results 2: ",
        "  Arm/Group Title: Fulvestrant 250 mg + Loading Dose",
        "  Arm/Group Description: Fulvestrant 250 mg + Loading Dose",
        "  Overall Number of Participants Analyzed: 51",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of patients  5.9        (1.2 to 16.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/47 (8.51%)",
        "  Anaemia 0/47 (0.00%)",
        "  Myocardial Infarction 0/47 (0.00%)",
        "  Macular Hole 1/47 (2.13%)",
        "  Diverticulum Intestinal Haemorrhagic 0/47 (0.00%)",
        "  Melaena 0/47 (0.00%)",
        "  Pain 0/47 (0.00%)",
        "  Pneumonia 0/47 (0.00%)",
        "  Hip Fracture 0/47 (0.00%)",
        "  Meniscus Lesion 1/47 (2.13%)",
        "  Amnesia 0/47 (0.00%)",
        "  Ischaemic Stroke 1/47 (2.13%)",
        "  Depression 0/47 (0.00%)",
        "Adverse Events 2:",
        "  Total: 9/50 (18.00%)",
        "  Anaemia 1/50 (2.00%)",
        "  Myocardial Infarction 1/50 (2.00%)",
        "  Macular Hole 0/50 (0.00%)",
        "  Diverticulum Intestinal Haemorrhagic 1/50 (2.00%)",
        "  Melaena 1/50 (2.00%)",
        "  Pain 0/50 (0.00%)",
        "  Pneumonia 0/50 (0.00%)",
        "  Hip Fracture 0/50 (0.00%)",
        "  Meniscus Lesion 0/50 (0.00%)",
        "  Amnesia 0/50 (0.00%)",
        "  Ischaemic Stroke 0/50 (0.00%)",
        "  Depression 1/50 (2.00%)"
    ]
}